Involvement of tryptophan hydroxylase 2 gene polymorphisms in susceptibility to tic disorder in Chinese Han population

Behavioral and Brain Functions

Ping Zheng²  Erzhen Li²  Jianhua Wang³  Xiaodai Cui¹  Liwen Wang² 

[1] Internal Medicine Laborary, Capital Institute of Pediatrics, Beijing, 100020, China

[2] Department of Neurological medicine, Capital Institute of Pediatrics, Beijing, 100020, China

[3] Department of Biotechnology, Capital Institute of Pediatrics, Beijing, 100020, China

关键词: Single nucleotide polymorphisms;    Tryptophan hydroxylase 2;    Tic disorder;   

Others  :  793683
DOI  :  10.1186/1744-9081-9-6

 received in 2012-06-19, accepted in 2013-01-22,  发布年份 2013

【 摘 要 】

Background

Tryptophan hydroxylase-2 (TPH2) is a potential candidate gene for screening tic disorder (TD).

Methods

A case–control study was performed to examine the association between the TPH2 gene and TD. The Sequenom® Mass ARRAY iPLEX GOLD System was used to genotype two single nucleotide polymorphisms (SNPs) of the TPH2 gene in 149 TD children and in 125 normal controls.

Results

For rs4565946, individuals with the TT genotype showed a significantly higher risk of TD than those with TC plus CC genotypes [odds ratio (OR) =3.077, 95% confidence interval (CI): 1.273–7.437; P = 0.009], as did male TD children with the TT genotype (OR = 3.228, 95% CI: 1.153–9.040; P = 0.020). The G allele of rs4570625 was significantly more frequent in TD children with higher levels of tic symptoms (Yale Global Tic Severity Scale, YGTSS) than those in controls among the male children (OR = 1.684, 95%: 1.097–2.583; P = 0.017]. TD children with severe tic symptoms had significantly higher frequencies of rs4546946 TT genotype than did normal controls in boys (OR = 3.292, 95% CI: 1.139–9.513; P = 0.022). We also found that genotype distributions of both SNPs were different between the Asian and European populations.

Conclusions

Our results indicated that the TT genotype of rs4565946 is a potential genetic risk factor for TD, and the allele G of rs4570625 might be associated with the severity of tic symptoms in boys. These polymorphisms might be susceptibility loci for TD in the Chinese Han population. Because of the confounding of co-existing attention deficit hyperactivity disorder (ADHD),these findings need to be confirmed by studies in much larger samples.

【 授权许可】

   
2013 Zheng et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Bloch M, State M, Pittenger C: Recent advances in Tourette syndrome. Curr Opin Neurol 2011, 24:119-125.
• [2]Singer HS: Tourette syndrome and other tic disorders. Handb Clin Neurol 2011, 100:641-657.
• [3]Cath DC, Hedderly T, Ludolph AG, Stern JS, Murphy T, Hartmann A, Czernecki V, Robertson MM, Martino D, Munchau A, Rizzo R, ESSTS Guidelines Group: European clinical guidelines for Tourette syndrome and other tic disorders. Part I: assessment. Eur Child Adolesc Psychiatry 2011, 20:155-171.
• [4]Khalifa N, Von Knorring AL: Prevalence of tic disorders and Tourette syndrome in a Swedish school population. Dev Med Child Neurol 2003, 45:315-319.
• [5]Peterson BS, Pine DS, Cohen P, Brook JS: Prospective, longitudinal study of tic, obsessive-compulsive, and attention-deficit/hyperactivity disorders in an epidemiological sample. J Am Acad Child Adolesc Psychiatry 2001, 40:685-695.
• [6]Robertson MM: Diagnosing Tourette syndrome: is it a common disorder? J Psychosom Res 2003, 55:3-6.
• [7]Wang HS, Kuo MF: Tourette’s syndrome in Taiwan: an epidemiological study of tic disorders in an elementary school at Taipei County. Brain Dev 2003, 25(Suppl 1):S29-S31.
• [8]Grados MA, Mathews CA: Clinical phenomenology and phenotype variability in Tourette syndrome. J Psychosom Res 2009, 67:491-496.
• [9]Hyde TM, Aaronson BA, Randolph C, Rickler KC, Weinberger DR: Relationship of birth weight to the phenotypic expression of Gilles de la Tourette’s syndrome in monozygotic twins. Neurology 1992, 42:652-658.
• [10]Kano Y, Ohta M, Nagai Y, Pauls DL, Leckman JF: A family study of Tourette syndrome in Japan. Am J Med Genet 2001, 105:414-421.
• [11]McMahon WM, Carter AS, Fredine N, Pauls DL: Children at familial risk for Tourette’s disorder: child and parent diagnoses. Am J Med Genet B Neuropsychiatr Genet 2003, 121B:105-111.
• [12]Price RA, Kidd KK, Cohen DJ, Pauls DL, Leckman JF: A twin study of Tourette syndrome. Arch Gen Psychiatry 1985, 42:815-820.
• [13]Deng H, Gao K, Jankovic J: The genetics of tourette syndrome. Nat Rev Neurol 2012, 8(4):203-213.
• [14]O’ Rourke JA, Scharf JM, Yu D, Pauls DL: The genetic of Tourette syndrome: a review. J Psychosom Res 2009, 67(6):533-545.
• [15]Behen M, Chugani HT, Juhasz C, Helder E, Ho A, Maqbool M, Rothermel RD, Perry JM, Uzik O: Abnormal brain tryptophan metabolism and clinical correlates in Tourette syndrome. Mov Disord 2007, 22:2256-2262.
• [16]Steeves TD, Fox SH: Neurobiological basis of serotonin-dopamine antagonists in the treatment of Gilles de la Tourette syndrome. Prog Brain Res 2008, 172:495-513.
• [17]Wong DF, Brasic JR, Singer HS, Schretlen DJ, Kuwabara H, Zhou Y, Nandi A, Maris MA, Alexander M, Ye W, et al.: Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET. Neuropsychopharmacology 2008, 33:1239-1251.
• [18]Walther DJ, Bader M: A unique central tryptophan hydroxylase isoform. Biochem Pharmacol 2003, 66:1673-1680.
• [19]Walther DJ, Peter JU, Bashammakh S, Hortnagl H, Voits M, Fink H, Bader M: Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 2003, 299:76.
• [20]Chen GL, Miller GM: Advances in tryptophan hydroxylase-2 gene expression regulation: new insights into serotonin-stress interaction and clinical implications. Am J Med Genet B Neuropsychiatr Genet 2012, 159B:152-171.
• [21]Breidenthal SE, White DJ, Glatt CE: Identification of genetic variants in the neuronal form of tryptophan hydroxylase (TPH2). Psychiatr Genet 2004, 14:69-72.
• [22]Zhang X, Beaulieu JM, Gainetdinov RR, Caron MG: Functional polymorphisms of the brain serotonin synthesizing enzyme tryptophan hydroxylase-2. Cell Mol Life Sci 2006, 63:6-11.
• [23]Lim JE, Pinsonneault J, Sadee W, Saffen D: Tryptophan hydroxylase 2 (TPH2) haplotypes predict levels of TPH2 mRNA expression in human pons. Mol Psychiatry 2007, 12:491-501.
• [24]Brown SM, Peet E, Manuck SB, Williamson DE, Dahl RE, Ferrell RE, Hariri AR: A regulatory variant of the human tryptophan hydroxylase-2 gene biases amygdala reactivity. Mol Psychiatry 2005, 10:884-888.
• [25]Inoue H, Yamasue H, Tochigi M, Takei K, Suga M, Abe O, Yamada H, Rogers MA, Aoki S, Sasaki T, Kasai K: Effect of Tryptophan hydroxylase-2 gene variants on amygdalar and hippocampal volumes. Brain Res 2010, 1331:51-57.
• [26]Chen GL, Vallender EJ, Miller GM: Functional characterization of the human TPH2 5’ regulatory region: untranslated region and polymorphisms modulate gene expression in vitro. Hum Genet 2008, 122:645-657.
• [27]Mossner R, Muller-Vahl KR, Doring N, Stuhrmann M: Role of the novel tryptophan hydroxylase-2 gene in Tourette syndrome. Mol Psychiatry 2007, 12:617-619.
• [28]Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, Cohen DJ: The yale global tic severity scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 1989, 28:566-573.
• [29]Association AP: Diagnostic and statistical manual of mental disorders: DSM-IV-TR. American Psychiatric Publishing, Inc; 2000.
• [30]Scheuch K, Lautenschlager M, Grohmann M, Stahlberg S, Kirchheiner J, Zill P, Heinz A, Walther DJ, Priller J: Characterization of a functional promoter polymorphism of the human tryptophan hydroxylase 2 gene in serotonergic raphe neurons. Biol Psychiatry 2007, 62:1288-1294.
• [31]Baehne CG, Ehlis AC, Plichta MM, Conzelmann A, Pauli P, Jacob C, Gutknecht L, Lesch KP, Fallgatter AJ: Tph2 gene variants modulate response control processes in adult ADHD patients and healthy individuals. Mol Psychiatry 2009, 14:1032-1039.
• [32]Waider J, Araragi N, Gutknecht L, Lesch KP: Tryptophan hydroxylase-2 (TPH2) in disorders of cognitive control and emotion regulation: a perspective. Psychoneuroendocrinology 2011, 36:393-405.
• [33]Leckman JF, Goodman WK, Anderson GM, Riddle MA, Chappell PB, McSwiggan-Hardin MT, McDougle CJ, Scahill LD, Ort SI, Pauls DL, et al.: Cerebrospinal fluid biogenic amines in obsessive compulsive disorder, Tourette’s syndrome, and healthy controls. Neuropsychopharmacology 1995, 12:73-86.